Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ventyx Biosciences, Inc.

1.59
+0.14009.66%
Post-market: 1.59-0.0010-0.06%18:45 EDT
Volume:1.69M
Turnover:2.62M
Market Cap:113.15M
PE:-0.91
High:1.62
Open:1.44
Low:1.38
Close:1.45
Loading ...

Morgan Stanley Sticks to Its Hold Rating for Ventyx Biosciences (VTYX)

TIPRANKS
·
19 May

Piper Sandler Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)

TIPRANKS
·
09 May

Ventyx Biosciences Q1 EPS $(0.39) Beats $(0.49) Estimate

Benzinga
·
09 May

Ventyx Biosciences Reports Q1 2025 Results: Net Loss Narrows to $27.4M, Down from $38.6M in 2024, as R&D Expenses Decrease

Reuters
·
09 May

BRIEF-Ventyx Biosciences Q1 EPS USD -0.39

Reuters
·
09 May

Ventyx Biosciences Q1 EPS USD -0.39

THOMSON REUTERS
·
09 May

Press Release: Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Dow Jones
·
01 Apr

Insiders' US$1.26m Investments In Red Following Ventyx Biosciences' US$11m Dip In Market Value

Simply Wall St.
·
31 Mar

Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX), Black Diamond Therapeutics (BDTX) and Passage Bio (PASG)

TIPRANKS
·
07 Mar

Ventyx Biosciences Reports 2024 Financial Results and Progress

TIPRANKS
·
05 Mar

Analysts’ Top Healthcare Picks: Genfit (GNFTF), Ventyx Biosciences (VTYX)

TIPRANKS
·
02 Mar

Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX) and Ocugen (OCGN)

TIPRANKS
·
02 Mar

Ventyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory Challenges

TIPRANKS
·
01 Mar

Ventyx Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Mar

LifeSci Capital Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)

TIPRANKS
·
01 Mar

H.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)

TIPRANKS
·
28 Feb

Ventyx Biosciences Q4 EPS $(0.41) Beats $(0.54) Estimate

Benzinga
·
28 Feb

BRIEF-Ventyx Biosciences Q4 EPS USD -0.41

Reuters
·
28 Feb

Press Release: Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Dow Jones
·
28 Feb

Ventyx Biosciences Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
22 Feb